Clinical trial
Recent-Onset Type 1 Diabetes Trial Evaluating Efficacy and Safety of Teplizumab
NCT03875729
Study timeline
Study start (actual)2019-04-05Date precision: day
Registry last updated2024-04-24
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Type 1 Diabetes Mellitusunresolved
Interventions
teplizumabBIOLOGICAL
PlaceboBIOLOGICAL
Sponsors & collaborators
Provention Bio, Inc.lead sponsor
Mapped research locations
WarsawPoland3ClevelandOhio, United States2ChicagoIllinois, United States1PhiladelphiaPennsylvania, United States1DallasTexas, United States1St LouisMissouri, United States1AtlantaGeorgia, United States1MiamiFlorida, United States1NashvilleTennessee, United States1San FranciscoCalifornia, United States1SeattleWashington, United States1San DiegoCalifornia, United States1
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT03875729 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.